Vasomune Therapeutics, Inc., recently announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for AV-001 for the prevention or treatment of moderate-to-severe ARDS in patients hospitalized with viral and/or bacterial respiratory infections. AV-001 is a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor which plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space.
Vasomune Therapeutics is an OBIO® member, an alumnus of our CAAP® program, and presented at the OBIO® Investment Summit.